* Cytosorbents Corp reported a quarterly adjusted loss of 12 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -15 cents to -10 cents per share.
* Revenue rose 3.6% to $9.79 million from a year ago; analysts expected $9.78 million.
* Cytosorbents Corp's reported EPS for the quarter was a loss of 12 cents.
* The company reported a quarterly loss of $6.36 million.
* Cytosorbents Corp shares had fallen by 8.2% this quarter and lost 21.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 7.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Cytosorbents Corp is $4.00 This summary was machine generated from LSEG data May 9 at 10:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.12 -0.12 Met
Dec. 31 2023 -0.14 -0.13 Beat
Sep. 30 2023 -0.14 -0.21 Missed
Jun. 30 2023 -0.11 -0.14 Missed
Comments